Cannabis Law and Access in Peru

Peru's cannabis law is more layered than most headlines suggest

Roughly 33 million people live under a legal framework that permits medical cannabis , and most English-language commentary reduces it to a single line: "Peru legalised it in 2017." That line is true, but it leaves out the part where implementation took years, the regulatory machinery was built almost from scratch, and personal cultivation was a contested point all the way through. I spent a few evenings last month working through the Spanish-language official gazette texts and the DIGEMID (Dirección General de Medicamentos, Insumos y Drogas) circulars , the rough equivalent of what I do here with the TGA's consultation papers , and the story is worth telling properly.

A quick note for Australian readers before we go anywhere: this article describes Peruvian law only. It has no bearing on what is legal in Australia. Cannabis in Australia is regulated under the Therapeutic Goods Act 1989, the Poisons Standard, and the TGA's access pathways. If you're in Australia and curious how those work locally, our pages on the Special Access Scheme, Authorised Prescriber pathway, and Schedule 8 (Controlled Drug) classification are a better starting point.

The 2017 law and what it actually said

Peru's Ley N° 30681, passed in November 2017, was the foundational instrument. It authorised the medical and therapeutic use of cannabis and its derivatives, and; critically, created a licensing regime for importation, production, research, and commercialisation. Recreational use was not legalised; possession for non-medical purposes remained a criminal matter under the Código Penal.

The law also created a registry system. Patients, caregivers, and associations seeking to cultivate for personal or community use were required to register with DIGEMID. This bit caused genuine friction. The registry did not open promptly in 2017; implementation regulations (Decreto Supremo N° 005-2019-SA) weren't published until 2019, and enforcement was inconsistent in the intervening period. Associations of patients and families, many of them advocates who had been pressing for legalisation for years; operated in legal grey zones while the machinery caught up.

By my reading, this is actually a pretty common pattern in cannabis reform globally. The law passes, the headlines run, and then the regulatory architecture takes two to four years to become functional. Australia's own TGA scheduling changes for cannabidiol (CBD) in 2021, moving low-dose CBD to Schedule 3, had a similar gap between the announcement and any genuine retail availability. Anyway.

What the framework permits today

Under the current regime, Peru permits:

• Medical and therapeutic use of cannabis derivatives (including products containing THC and CBD) with a medical prescription and DIGEMID registration.
• Licensed importation of cannabis-derived medicinal products that comply with the Registro Sanitario (sanitary registry) requirements; Peru's rough equivalent of the ARTG (Australian Register of Therapeutic Goods).
• Licensed domestic production by companies and non-profit associations that hold a DIGEMID licence. Both cultivation and processing are in scope.
• Individual and association-based cultivation for personal therapeutic use, subject to registry with DIGEMID and quantity limits established by regulation.
• Scientific research under a separate research licence category.

Recreational use remains prohibited. THC-containing cannabis sits in a controlled category. The key regulator is DIGEMID, operating under the Ministerio de Salud (Ministry of Health), with additional oversight from DEVIDA (Comisión Nacional para el Desarrollo y Vida sin Drogas) on the anti-narcotics side. That split between health and law enforcement oversight is worth noting, it creates some jurisdictional complexity that practitioners navigating the system have flagged publicly.

The 2021 amendment: personal cultivation clarified

A significant amendment came through in 2021. The Peruvian Congress passed modifications that more explicitly protected individual cultivation rights for registered patients and their caregivers, clarifying that registered persons cultivating for personal therapeutic use should not face criminal prosecution provided they met the registry and quantity requirements.

This was not a trivial clarification. Before it, law enforcement interpretation of what was and wasn't protected had been inconsistent across regions. The 2021 reform was partly driven by documented cases of registered patients having plants seized despite holding valid DIGEMID registrations, situations that the health ministry and the police had different views on. The amendment was intended to bring those views into alignment.

Whether implementation has been fully uniform since is harder to assess from published sources. The UNODC's World Drug Report 2023 notes that Latin American cannabis frameworks continue to show gaps between formal law and on-the-ground enforcement practice.

Product standards and what's on the market

Licensed products in Peru must meet quality standards set by DIGEMID, which include requirements for labelling, standardised content declaration, and; for imported products, evidence of manufacturing compliance in the country of origin. This is broadly analogous to the Good Manufacturing Practice requirements that apply to cannabis medicines in Australia (see our GMP glossary page on Good Manufacturing Practice).

In practice, most licensed products available in Peru are CBD-dominant preparations, with higher-THC pharmaceutical products being far less common on the legal market. This reflects both supply-chain realities and prescriber caution. Products derived from hemp (low-THC cannabis) occupy a somewhat different regulatory space, though the boundary between "hemp product" and "cannabis medicine" in Peruvian regulation has not always been drawn with perfect clarity, something I'd argue is a structural weakness in the framework, not just an administrative quirk.

For readers interested in the chemistry: the cannabinoid profile of registered products; how much CBD, THC, and minor cannabinoids like CBG a product contains, must be declared. Whether preparations qualify as full-spectrum, broad-spectrum, or isolate is relevant to product type classification, though those terms don't appear in the Peruvian regulatory text in quite the same way they appear in AU market discourse.

How Peru sits in the regional picture

Peru is one of a cluster of Latin American countries, alongside Uruguay (which went further with adult-use legalisation in 2013), Colombia, Argentina, Chile, Brazil, and Mexico; that have reformed cannabis laws since roughly 2015. The region has moved faster than many expected, driven by a combination of patient advocacy, Constitutional Court rulings in some jurisdictions, and a broad rethink of prohibitionist drug policy frameworks.

Peru's approach is more conservative than Colombia's, which has a longer-running licensed production industry and a significant export sector. It's broadly comparable to Chile and Argentina in terms of the medical-only model with patient-registration mechanisms. None of these frameworks are directly comparable to Australia's, our TGA-centred model, with its specific prescription pathways and manufacturing standards, is its own thing.

I'll admit the comparative regulatory work is genuinely interesting from a policy analysis angle. I had a look at these frameworks during a long road ride weekend, pulled over at the servo just past Hall in the ACT to jot down some notes, which my riding partner found less amusing than I did. But the structural parallels between how Peru and Australia each tried to thread the needle between access and control are striking if you spend enough time with the texts.

What Australian readers should take from this

If you're an Australian researching cannabis law internationally; for academic, journalistic, or policy reasons, Peru's framework is a useful case study in how medical legalisation plays out when implementation lags behind legislation. The 2017 law created the right, but the actual access infrastructure took years to build.

This article describes Peruvian law only. It does not constitute legal advice for any jurisdiction. If you are in Australia and seeking information about how cannabis medicines are accessed lawfully here, please refer to TGA guidance directly at tga.gov.au. The relevant Australian access pathways, the Special Access Scheme and the Authorised Prescriber programme; require involvement of a registered medical practitioner. Cannabis medicines in Australia containing THC above the Schedule 4 threshold are Schedule 8 controlled drugs. Possession or supply outside of lawful prescription is a criminal offence under state and territory law.

Sources

• Decreto Supremo N° 005-2019-SA, Ministerio de Salud, Perú (MINSA)
• World Drug Report 2023, United Nations Office on Drugs and Crime (UNODC)
• Accessing Cannabis Medicines; Therapeutic Goods Administration (TGA)
• Medical Cannabis Regulation in Latin America: A Comparative Review, NCBI/PubMed Central

, Marcus Hale, Regulatory researcher, TGA & access law